Q-omics provides the consensus-scored GAMT profile across patient tissues and cancer cell-line models. GAMT expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GAMT is differentially expressed in 13, with the highest sampling consensus in STAD. Additionally, GAMT protein abundance shows 22,049 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight ACC, STAD, and BRCA as cancer lineages where GAMT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAMT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAMT survival associations across molecular data types. GAMT RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAMT RNA expression–survival associations across cancer types. High GAMT expression shows unfavorable associations in ACC, BLCA, MESO and STAD, but favorable associations in KIRC and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GAMT RNA expression.
This table summarizes GAMT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in STAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for GAMT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAMT shows lower tumor expression in STAD, BLCA and KICH and higher tumor expression in LUAD, KIRC and LUSC. The STAD box plot shows higher GAMT RNA expression in normal versus tumor tissue (log2 FC = −1.896, t-test p < 0.001).
This table shows molecular features associated with GAMT in patient tissues and cancer cell lines. In patient samples, GAMT shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, GAMT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and SKIN.
